Literature DB >> 19199891

Metabolic control and diabetic retinopathy.

Monica Rodriguez-Fontal1, John B Kerrison, D Virgil Alfaro, Eric P Jablon.   

Abstract

The Early Treatment Diabetic Retinopathy Study (ETDRS) identified important risk factors for progression to high risk proliferative diabetic retinopathy (PDR) including retinopathy severity, decreased visual acuity, and high levels of hemoglobin A1C (HbA1c). Additional risk factors for progression to PDR are decreased hematocrit and increased serum lipids. The long-term benefit of improving glycemic control was evaluated by three large studies: the Diabetes Control and Complications Trial (DCCT), the Stockholm Interventional Study, and the UK prospective study. Several small studies, notably the Kuwamoto study, also evaluated the relationship between the glycemic control and diabetic retinopathy. Intensive glycemic control reduces the risk of any retinopathy by approximately 27%. Intensive therapy is most effective when initiated early in the course of the diabetes, demonstrating a beneficial effect over the course and progression of retinopathy. The long term benefits of the intensive glycemic control greatly outweigh the risk of "early worsening." Lowering elevated serum lipid levels has been shown to decrease the risk of cardiovascular morbidity. The ETDRS data suggest that lipid lowering may also decrease the risk of hard exudate formation and associated vision loss in patients with diabetic retinopathy. Preservation of vision may be an additional motivating factor for lowering serum lipid levels in persons with diabetic retinopathy and elevated serum lipid levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19199891     DOI: 10.2174/157339909787314176

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  13 in total

Review 1.  Diabetic retinopathy - ocular complications of diabetes mellitus.

Authors:  Martin M Nentwich; Michael W Ulbig
Journal:  World J Diabetes       Date:  2015-04-15

Review 2.  Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.

Authors:  Dilsher S Dhoot; Robert L Avery
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

3.  Extended targeted retinal photocoagulation versus conventional pan-retinal photocoagulation for proliferative diabetic retinopathy in a randomized clinical trial.

Authors:  Homayoun Nikkhah; Hossein Ghazi; Mohammad Reza Razzaghi; Saeed Karimi; Alireza Ramezani; Masoud Soheilian
Journal:  Int Ophthalmol       Date:  2017-02-06       Impact factor: 2.031

4.  Risk factors associated with diabetic retinopathy in patients with diabetes mellitus type 2.

Authors:  Irini P Chatziralli; Theodoros N Sergentanis; Petros Keryttopoulos; Nikolaos Vatkalis; Antonis Agorastos; Leonidas Papazisis
Journal:  BMC Res Notes       Date:  2010-06-01

Review 5.  Emerging pharmacotherapies for diabetic macular edema.

Authors:  Golnaz Javey; Stephen G Schwartz; Harry W Flynn
Journal:  Exp Diabetes Res       Date:  2012-02-26

6.  Risk factors of retinopathy in type 2 diabetes mellitus at a tertiary care hospital, Bahawalpur Pakistan.

Authors:  Sadiq Hussain; Muhammad Rashad Qamar; Muhammad Arshad Iqbal; Ameer Ahmad; Ehsan Ullah
Journal:  Pak J Med Sci       Date:  2013-04       Impact factor: 1.088

7.  Effect of diabetic retinopathy and diabetes on the intraocular straylight in pseudophakic eyes.

Authors:  Hyung Bin Hwang; Hye Bin Yim; Sung Kun Chung
Journal:  BMC Ophthalmol       Date:  2015-10-13       Impact factor: 2.209

8.  Pattern Visual Evoked Potential Changes in Diabetic Patients without Retinopathy.

Authors:  Ozgur Balta; Gulten Sungur; Mehmet Yakin; Nurten Unlu; Oyku Bezen Balta; Firdevs Ornek
Journal:  J Ophthalmol       Date:  2017-03-14       Impact factor: 1.909

9.  Lipoprotein(a) serum levels in diabetic patients with retinopathy.

Authors:  Giulia Malaguarnera; Caterina Gagliano; Claudio Bucolo; Marco Vacante; Salvatore Salomone; Michele Malaguarnera; Daniela Giovanna Leonardi; Massimo Motta; Filippo Drago; Teresio Avitabile
Journal:  Biomed Res Int       Date:  2013-06-05       Impact factor: 3.411

Review 10.  Does tight control of systemic factors help in the management of diabetic retinopathy?

Authors:  Ramachandran Rajalakshmi; Vijayaraghavan Prathiba; Viswanathan Mohan
Journal:  Indian J Ophthalmol       Date:  2016-01       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.